Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  17 (2025)
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 17 , ISSUE 1 ( January-February, 2025 ) > List of Articles

RESEARCH ARTICLE

Analysis of the Malignancy Risk of Endometriosis and Ovarian Cancer Related to Endometriosis-associated Ovarian Cancer: A Histopathological Review and Genetic Mutation

Heru Priyanto, Uki R Budihastuti, Eriana Melinawati, Affi A Ratnasari, Grace KT Siagian, Ichsanul A Himawan, Alfian A Sunanto, Yonathan S Pratama

Keywords : ARID1A, BRAF, Endometriosis, Endometriosis-associated ovarian cancer, Ovarian cancer, p53

Citation Information : Priyanto H, Budihastuti UR, Melinawati E, Ratnasari AA, Siagian GK, Himawan IA, Sunanto AA, Pratama YS. Analysis of the Malignancy Risk of Endometriosis and Ovarian Cancer Related to Endometriosis-associated Ovarian Cancer: A Histopathological Review and Genetic Mutation. J South Asian Feder Obs Gynae 2025; 17 (1):34-38.

DOI: 10.5005/jp-journals-10006-2600

License: CC BY-NC 4.0

Published Online: 28-03-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Aims and background: Ovarian cancer and endometriosis are common in Indonesia, with 13,310 new ovarian cancer cases reported annually and an endometriosis prevalence ranging from 13.6 to 69.5%. Endometriosis can lead to endometriosis-associated ovarian cancer (EAOC), yet the relationship between EAOC risk and genetic mutations, such as AT-rich interaction domain 1A (ARID1A), B-raf proto-oncogene (BRAF), and p53 remains unexplored. This study aims to evaluate and predict the risk of malignancy in EAOC through histopathological analysis and genetic mutation testing. Materials and methods: At Dr Moewardi General Hospital in Surakarta, Indonesia, we involved 60 patients with endometriosis and ovarian cancer in an observational analytical study with a retrospective case-control design. Our study investigates the risk of EAOC and examines the impact of histopathological findings and ARID1A, BRAF, and p53 gene mutations. We used histopathological exams to analyze the samples. For statistical analysis, we employed the Kruskal–Wallis and Mann–Whitney U tests. Results: A significant difference (p < 0.001) in the expression of ARID1A, BRAF, and p53 genes was observed across different histopathological types of endometriosis and ovarian cancer. Conclusion: Histopathological analysis of endometriosis types, along with the expression of ARID1A, BRAF, and p53 mutations, could act as biomarkers for predicting the malignant transformation into ovarian cancer (EAOC). Clinical significance: These gene expressions are associated with the risk of progression from both typical and atypical endometriosis to ovarian cancer or EAOC.

PDF Share
  1. Acién P, Velasco I, Acién M, et al. Epithelial ovarian cancers and endometriosis. Gynecol Obstet Invest 2015;79(2):126−135. DOI: 10.1159/000367597.
  2. Grandi G, Toss A, Cortesi L, et al. The association between endometriomas and ovarian cancer: Preventive effect of inhibiting ovulation and menstruation during reproductive life. Biomed Res Int 2015;2015:751571. DOI: 10.1155/2015/751571.
  3. Purwoko M. Hubungan tingkat pendidikan dan pekerjaan dengan tingkat pengetahuan mengenai kanker ovarium pada wanita. Mutiara Medika: Jurnal Kedokteran dan Kesehatan 2018;18(2):45−48. DOI: 10.18196/mm.180214.
  4. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359−E386. DOI: 10.1002/ijc.29210.
  5. Bartiromo L, Schimberni M, Villanacci R, et al. A systematic review of atypical endometriosis-associated biomarkers. Int J Mol Sci 2022;23(8):4425. DOI: 10.3390/ijms23084425.
  6. Sun Y, Liu G. Endometriosis-associated ovarian clear cell carcinoma: A special entity? J Cancer 2021;12(22):6773−6786. DOI: 10.7150/jca.61107.
  7. Mathur R. ARID1A loss in cancer: Towards a mechanistic understanding. Pharmacol Ther 2018;190:15−23. DOI: 10.1016/j.pharmthera.2018.05.001.
  8. Xiao L, Wang D, Ma Y, et al. Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis. Int J Mol Med 2018;41(3):1349−1356. DOI: 10.3892/ijmm.2017.3342.
  9. Hoseini MS, Rashidnahal M, Ebrahimi A, et al. Association between single nucleotide polymorphism rs113488022 of BRAF and endometriosis in Iranian population. J Tissues Mater 2018;1(1):25−31. DOI: 10.22034/jtm.2018.69395.
  10. Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: From molecular mechanism to therapeutic modulation. Cell Death Dis 2022;13(11):974. DOI: 10.1038/s41419-022-05408-1.
  11. Khalique S, Naidoo K, Attygalle AD, et al. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. J Pathol Clin Res 2018;4(3):154−166. DOI: 10.1002/cjp2.103.
  12. Szymonek M, Kowalik A, Kopczyński J, et al. Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma. Oncotarget 2017;8(43):74897−74909. DOI: 10.18632/oncotarget.20451.
  13. Gow CH, Hsieh MS, Lin YT, et al. Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas. Cancers (Basel) 2019;11(6):866. DOI: 10.3390/cancers11060866.
  14. Schirosi L, Strippoli S, Gaudio F, et al. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression of disease in melanoma patients? BMC Cancer 2016;16(1):2951. DOI: 10.1186/s12885-016-2951-4.
  15. Köbel M, Ronnett BM, Singh N, et al. Interpretation of p53 immunohistochemistry in endometrial carcinomas: Toward increased reproducibility. Int J Gynecol Pathol 2019;38(1):S123−S131. DOI: 10.1097/PGP.0000000000000488.
  16. Köbel M, Kang EY. The many uses of p53 immunohistochemistry in gynecological pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP annual meeting. Int J Gynecol Pathol 2021;40(1):32−40. DOI: 10.1097/PGP.0000000000000725.
  17. Ali AT, Al-ani O, Al-ani F. Epidemiology and risk factors for ovarian cancer. Menopausal Rev 2023;22(2):93−104. DOI: 10.5114/pm.2023.128661.
  18. Moradi Y, Shams-Beyranvand M, Khateri S, et al. A systematic review on the prevalence of endometriosis in women. Indian J Med Res 2021;154(3):446. DOI: 10.4103/ijmr.IJMR_817_18.
  19. Akbarzadeh-Jahromi M, Zare Z, Sari Aslani F, et al. Evaluation of PTEN and Ki67 expression in typical and atypical endometriosis and endometriosis-associated ovarian cancer. Shiraz E Med J 2020;21(11):e99291. DOI: 10.5812/semj.99291.
  20. Charkhchi P, Cybulski C, Gronwald J, et al. CA125 and ovarian cancer: A comprehensive review. Cancers (Basel) 2020;12(12):3730. DOI: 10.3390/cancers12123730.
  21. Chen T, Wei J, Leng T, et al. The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis. J Clin Lab Anal 2021;35(9). DOI: 10.1002/jcla.23947.
  22. Capozzi VA, Scarpelli E, dell'Omo S, et al. Atypical endometriosis: A comprehensive systematic review of pathological patterns and diagnostic challenges. Biomedicines 2024;12(6):1209. DOI: 10.3390/biomedicines12061209.
  23. Won S, Cho YJ, Lee N, et al. Atypical endometriosis is related to a higher recurrence rate. Eur J Obstet Gynecol Reprod Biol 2020;254:44−51. DOI: 10.1016/j.ejogrb.2020.08.054.
  24. So KA, Hong SR, Kim NR, et al. Association between atypical endometriosis and ovarian malignancies in the real world. J Ovarian Res 2021;14(1):110. DOI: 10.1186/s13048-021-00865-2.
  25. Sevilla IN, Linde FM, Sánchez MPM, et al. Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosis-associated ovarian cancer. J Gynecol Oncol 2019;30(4):e63. DOI: 10.3802/jgo.2019.30.e63.
  26. Widyawati R, Siregar B, Kusmardi K. Decreased expressions of ARID1A in non-atypical, atypical endometriosis cysts and ovarian clear cell carcinoma as a biomarker of malignancy transformations. In: 4th International Symposium of Biomedical Engineering's Recent Progress in Biomaterials, Drugs Development, Health, and Medical Devices, ISBE 2019. 2019 July 22−24; Padang, West Sumatera: Indonesia; 2019. p. 040010.
  27. de la Cuesta RS, Izquierdo M, Cañamero M, et al. Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;113(1):87−93. DOI: 10.1016/S0301-2115(03)00367-1.
  28. Stavropoulos A, Varras M, Vasilakaki T, et al. Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. Oncol Lett 2019;17(4):4003−4009. DOI: 10.3892/ol.2019.10093.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.